
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), meeting the study's primary endpoint.
FOP is a rare genetic disorder in which muscle, tendon, and ligament tissue progressively turn into bone, creating a "second skeleton" that limits mobility.